強気
$155.14
シナリオ価格
$130.430
+2.243 (+1.72%)終値時点
Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, and vascular access. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of the MANTA Vascular Closure device, Arrow OnControl powered bone biopsy system, GuideLiner, Turnpike and TrapLiner catheters.
Teleflex Inc is a good buy right now, with a current price of $130.43 and a forward P/E of 11.01, indicating potential for growth. The recent upgrade from BofA reflects confidence in the company's new management and execution, which could lead to better-than-expected organic growth. Additionally, the stock has shown a 5-day change of +4.24%, suggesting positive momentum. However, the main risk is the high debt to equity ratio of 96.68%, which could impact financial stability if not managed properly.
BofA
$158
2026-09-28
BofA
2026-09-28
目標株価
$158
UBS
$158
2026-08-11
UBS
2026-08-11
目標株価
$158
Truist
$150
2026-08-10
Truist
2026-08-10
目標株価
$150
Raymond James
$155
2026-08-07
Raymond James
2026-08-07
目標株価
$155
Needham
$159
2026-07-31
Needham
2026-07-31
目標株価
$159
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

Teleflex Completes Patient Enrollment in BIOMAG™-LL Clinical Study

Key Wall Street Calls on Monday

Teleflex Appoints New Board Member Sean M. Salmon

Teleflex Unveils Dynetic-35 Stent System at CIRSE 2026

Teleflex Showcases Dynetic™-35 Stent System at CIRSE 2026
Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, and vascular access. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of the MANTA Vascular Closure device, Arrow OnControl powered bone biopsy system, GuideLiner, Turnpike and TrapLiner catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Teleflex Inc is a good buy right now, with a current price of $130.43 and a forward P/E of 11.01, indicating potential for growth. The recent upgrade from BofA reflects confidence in the company's new management and execution, which could lead to better-than-expected organic growth. Additionally, the stock has shown a 5-day change of +4.24%, suggesting positive momentum. However, the main risk is the high debt to equity ratio of 96.68%, which could impact financial stability if not managed properly.
12 analysts cover TFX: 10 rate it Buy, 2 Hold and 0 Sell. The average price target is 136.20.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。